TRILC.E — Turk Ilac ve Serum Sanayi AS Balance Sheet
0.000.00%
- TRY2.57bn
- TRY5.11bn
- TRY4.54bn
Annual balance sheet for Turk Ilac ve Serum Sanayi AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | Interim Report | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 44.8 | 36.9 | 6.44 | 9.05 | 11.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 265 | 398 | 852 | 1,958 | 2,672 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 381 | 536 | 974 | 2,724 | 4,633 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 238 | 416 | 1,081 | 2,177 | 1,960 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 620 | 1,044 | 2,243 | 5,229 | 6,884 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 259 | 412 | 771 | 1,396 | 4,460 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 295 | 480 | 827 | 2,710 | 5,262 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 324 | 565 | 1,416 | 2,518 | 1,622 |
| Total Liabilities & Shareholders' Equity | 620 | 1,044 | 2,243 | 5,229 | 6,884 |
| Total Common Shares Outstanding |